// App-Quantinova.ai

e16566 : Hypertension and impaired renal function as biomarkers of efficacy of bevacizumab (bev) in ovarian cancer: A retrospective study.

Researchers

Presenter

  • Audie Bercelle Bavouidibio

Principal Investigators

  • Reza-Thierry Elaidi

  • Hal Aboudagga

  • Stephane Oudard

  • Yann Orven

  • Marie Courbebaisse

  • Brigitte Sabatier

  • Gilles Chironi

  • Eric Pujade Lauraine

  • Fabrice Lecuru

  • Jacques Medioni

  • Mara Brizard

  • Pierre Combe

Medical Centers

  • Pharmacy Hospital an Georges Pompidou and INSERM UMR 1138/Paris Descartes University, Paris, France

  • Prevention of Cardiovascular Disease, Hopital en Georges Pompidou, and Paris Descartes University, Paris, France

  • Georges Pompidou Hospital, Paris, France

  • Pharmacy Department, Georges Pompidou an Hospital, Paris, France

  • Hopital en Georges Pompidou (HEGP), Assistance Publique Hopitaux de Paris (AP-HP), Paris, FranceGINECO/CHU Hotel Dieu, Paris, FranceDepartment of Medical Oncology, Georges Pompidou an Hospital, Paris, France

  • HEGP, Oncology Department, Paris, France

  • Hopital European Georges Pompidou, Paris, France

  • ARTIC Association, Paris, France

  • Pharmacy, Hopital en Georges Pompidou, Paris, France

  • Georges Pompidou Hospital, Paris, France

  • Physiology Department, Hopital en Georges Pompidou, and Paris Descartes University, Paris, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gynaecological cancer

  • Hypertension

  • Solid malignancies

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • Bevacizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved